Annual Total Liabilities
$45.07 M
-$2.65 M-5.54%
December 31, 2023
Summary
- As of February 8, 2025, ATNM annual total liabilities is $45.07 million, with the most recent change of -$2.65 million (-5.54%) on December 31, 2023.
- During the last 3 years, ATNM annual total liabilities has risen by +$39.99 million (+787.48%).
- ATNM annual total liabilities is now -5.54% below its all-time high of $47.71 million, reached on December 31, 2022.
Performance
ATNM Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Total Liabilities
$43.91 M
-$2.12 M-4.61%
September 30, 2024
Summary
- As of February 8, 2025, ATNM quarterly total liabilities is $43.91 million, with the most recent change of -$2.12 million (-4.61%) on September 30, 2024.
- Over the past year, ATNM quarterly total liabilities has dropped by -$1.16 million (-2.57%).
- ATNM quarterly total liabilities is now -7.98% below its all-time high of $47.71 million, reached on December 31, 2022.
Performance
ATNM Quarterly Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Total Liabilities Formula
Total Liabilities = Current Liabilities + Long-Term Liabilities
ATNM Total Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -5.5% | -2.6% |
| 3 y3 years | +787.5% | +946.9% |
| 5 y5 years | +641.6% | +588.0% |
ATNM Total Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -5.5% | +558.6% | -8.0% | +666.9% |
| 5 y | 5-year | -5.5% | +787.5% | -8.0% | +1010.1% |
| alltime | all time | -5.5% | >+9999.0% | -8.0% | >+9999.0% |
Actinium Pharmaceuticals Total Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $43.91 M(-4.6%) |
| Jun 2024 | - | $46.03 M(+3.4%) |
| Mar 2024 | - | $44.49 M(-1.3%) |
| Dec 2023 | $45.07 M(-5.5%) | $45.07 M(-0.7%) |
| Sep 2023 | - | $45.36 M(-1.3%) |
| Jun 2023 | - | $45.97 M(+2.6%) |
| Mar 2023 | - | $44.82 M(-6.1%) |
| Dec 2022 | $47.71 M(+597.2%) | $47.71 M(+4.7%) |
| Sep 2022 | - | $45.56 M(+4.5%) |
| Jun 2022 | - | $43.62 M(+661.9%) |
| Mar 2022 | - | $5.72 M(-16.3%) |
| Dec 2021 | $6.84 M(+34.8%) | $6.84 M(+63.2%) |
| Sep 2021 | - | $4.19 M(+6.0%) |
| Jun 2021 | - | $3.96 M(-9.3%) |
| Mar 2021 | - | $4.36 M(-14.1%) |
| Dec 2020 | $5.08 M(-15.7%) | $5.08 M(-0.4%) |
| Sep 2020 | - | $5.10 M(-1.6%) |
| Jun 2020 | - | $5.18 M(-3.0%) |
| Mar 2020 | - | $5.34 M(-11.3%) |
| Dec 2019 | $6.03 M(-0.8%) | $6.03 M(-5.6%) |
| Sep 2019 | - | $6.38 M(+4.3%) |
| Jun 2019 | - | $6.12 M(-11.2%) |
| Mar 2019 | - | $6.89 M(+13.4%) |
| Dec 2018 | $6.08 M(+30.2%) | $6.08 M(+47.4%) |
| Sep 2018 | - | $4.12 M(-21.7%) |
| Jun 2018 | - | $5.27 M(-17.6%) |
| Mar 2018 | - | $6.39 M(+37.0%) |
| Dec 2017 | $4.67 M(+3.2%) | $4.67 M(+32.2%) |
| Sep 2017 | - | $3.53 M(-14.0%) |
| Jun 2017 | - | $4.11 M(-23.5%) |
| Mar 2017 | - | $5.37 M(+18.8%) |
| Dec 2016 | $4.52 M(-2.0%) | $4.52 M(+49.3%) |
| Sep 2016 | - | $3.03 M(+21.7%) |
| Jun 2016 | - | $2.49 M(-24.3%) |
| Mar 2016 | - | $3.29 M(-28.8%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2015 | $4.61 M(-51.4%) | $4.61 M(+114.1%) |
| Sep 2015 | - | $2.16 M(-29.4%) |
| Jun 2015 | - | $3.05 M(-15.5%) |
| Mar 2015 | - | $3.61 M(-62.0%) |
| Dec 2014 | $9.49 M(+29.6%) | $9.49 M(-7.2%) |
| Sep 2014 | - | $10.23 M(-8.0%) |
| Jun 2014 | - | $11.12 M(-44.5%) |
| Mar 2014 | - | $20.03 M(+173.4%) |
| Dec 2013 | $7.33 M(+57.8%) | $7.33 M(+112.6%) |
| Sep 2013 | - | $3.45 M(-9.8%) |
| Jun 2013 | - | $3.82 M(+36.1%) |
| Mar 2013 | - | $2.81 M(-39.6%) |
| Dec 2012 | $4.64 M(-10.9%) | $4.64 M(+4364.6%) |
| Sep 2012 | - | $104.00 K(+3.6%) |
| Jun 2012 | - | $100.40 K(+6.7%) |
| Mar 2012 | - | $94.10 K(-98.2%) |
| Dec 2011 | $5.21 M(+5394.2%) | $5.21 M(+6267.4%) |
| Sep 2011 | - | $81.80 K(+4.5%) |
| Jun 2011 | - | $78.30 K(-20.7%) |
| Mar 2011 | - | $98.80 K(+4.2%) |
| Dec 2010 | $94.80 K(-3.7%) | $94.80 K(+10.0%) |
| Sep 2010 | - | $86.20 K(-22.7%) |
| Jun 2010 | - | $111.50 K(+5.4%) |
| Mar 2010 | - | $105.80 K(+7.5%) |
| Dec 2009 | $98.40 K(+29.1%) | $98.40 K(+10.7%) |
| Sep 2009 | - | $88.90 K(+4.5%) |
| Jun 2009 | - | $85.10 K(+4.4%) |
| Mar 2009 | - | $81.50 K(+7.0%) |
| Dec 2008 | $76.20 K(+69.3%) | $76.20 K(+11.1%) |
| Sep 2008 | - | $68.60 K(+5.1%) |
| Jun 2008 | - | $65.30 K(+17.0%) |
| Mar 2008 | - | $55.80 K(+24.0%) |
| Dec 2007 | $45.00 K(+138.1%) | $45.00 K(+28.6%) |
| Sep 2007 | - | $35.00 K(+54.2%) |
| Jun 2007 | - | $22.70 K(+20.1%) |
| Dec 2006 | $18.90 K | $18.90 K |
FAQ
- What is Actinium Pharmaceuticals annual total liabilities?
- What is the all time high annual total liabilities for Actinium Pharmaceuticals?
- What is Actinium Pharmaceuticals annual total liabilities year-on-year change?
- What is Actinium Pharmaceuticals quarterly total liabilities?
- What is the all time high quarterly total liabilities for Actinium Pharmaceuticals?
- What is Actinium Pharmaceuticals quarterly total liabilities year-on-year change?
What is Actinium Pharmaceuticals annual total liabilities?
The current annual total liabilities of ATNM is $45.07 M
What is the all time high annual total liabilities for Actinium Pharmaceuticals?
Actinium Pharmaceuticals all-time high annual total liabilities is $47.71 M
What is Actinium Pharmaceuticals annual total liabilities year-on-year change?
Over the past year, ATNM annual total liabilities has changed by -$2.65 M (-5.54%)
What is Actinium Pharmaceuticals quarterly total liabilities?
The current quarterly total liabilities of ATNM is $43.91 M
What is the all time high quarterly total liabilities for Actinium Pharmaceuticals?
Actinium Pharmaceuticals all-time high quarterly total liabilities is $47.71 M
What is Actinium Pharmaceuticals quarterly total liabilities year-on-year change?
Over the past year, ATNM quarterly total liabilities has changed by -$1.16 M (-2.57%)